Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective fatty acid synthase (FASN) inhibitors to treat metabolic dysfunction-associated steatohepatitis (MASH), acne, and select cancers caused by palmitate overproduction. The company's lead candidate, denifanstat, is an oral once-daily FASN inhibitor designed to reduce liver steatosis, inflammation, and fibrosis in MASH patients, while its second candidate, TVB-3567, targets acne; the company is also exploring denifanstat in combination with other agents for cirrhotic liver disease and in various cancer indications. Corvus is pre-commercial and generates no product revenue; it has licensed denifanstat rights in Greater China to a partner under a royalty-bearing agreement and retains development and commercialization rights elsewhere, with plans to either build its own sales infrastructure or partner with commercial collaborators based on market opportunity, while its intellectual property portfolio includes multiple issued patents with expirations extending into the 2030s and beyond.